Marlex Pharmaceuticals’ s 12,000ft² facility contains temperature-controlled space and is used for pharmaceutical packaging, contract packaging and private labeling.
The acquisition will increase revenues, order processing capability and provide opportunities to secure government contracts due to Marlex’s current relationships, according to ScripsAmerica.
ScripsAmerica CEO Bob Schneiderman said the acquisition of Marlex Pharmaceuticals is expected to increase ScripsAmerica’s annual revenues by up to $6m and operating income by up to 10 to 15%.
”This scope of growth would significantly increase shareholder value and mark the Company’s first major step toward becoming a complete provider of OTC and nutraceutical drugs, which includes the distribution and packaging of current product lines as well as the acquisition of new brands," Schneiderman added.
"We are very confident that the Company will raise the capital necessary to finalize this acquisition and expect it to contribute to our bottom line by the first quarter of 2013."
ScripsAmerica is planning to raise the necessary funds to complete the acquisition through a private placement of its equity or by securing debt securities.